JNJ's Janssen increased R&D spending, decreased list prices in 2017

The Janssen Pharmaceuticals unit of Johnson & Johnson (NYSE:JNJ) said it increased R&D spending and lowered annual rate changes of average list price and net price of drugs in 2017 vs. 2016. Data were published in its second annual 2017 Janssen U.S. Transparency Report.

Janssen reported $7.9 billion in R&D expenses in 2017, up 13% from 2016. The average list price went up 8.1%, vs. an 8.5% increase in 2016, while the average net price decreased 4.6%, vs. a 3.5% increase in 2016. For the year, Janssen offered about $15 billion in total drug discounts and rebates...